Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday

by · The Cerbat Gem

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expect Protagonist Therapeutics to post earnings of ($0.5415) per share and revenue of $14.9160 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 12:30 PM ET.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The business had revenue of $7.44 million during the quarter, compared to the consensus estimate of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. On average, analysts expect Protagonist Therapeutics to post $2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Protagonist Therapeutics Trading Down 3.2%

Shares of PTGX stock opened at $92.36 on Monday. The firm’s 50 day moving average is $85.52 and its 200 day moving average is $79.79. The stock has a market capitalization of $5.89 billion, a P/E ratio of -45.05 and a beta of 2.23. Protagonist Therapeutics has a 12 month low of $39.60 and a 12 month high of $98.32.

Insider Transactions at Protagonist Therapeutics

In related news, insider Arturo Md Molina sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $82.00, for a total value of $410,000.00. Following the transaction, the insider directly owned 84,115 shares in the company, valued at approximately $6,897,430. This represents a 5.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 4,068 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $83.19, for a total transaction of $338,416.92. Following the completion of the sale, the chief executive officer directly owned 574,505 shares in the company, valued at $47,793,070.95. This represents a 0.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 203,167 shares of company stock worth $16,889,199. 4.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Protagonist Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of PTGX. Vident Advisory LLC purchased a new stake in shares of Protagonist Therapeutics during the 3rd quarter valued at $337,000. Cibc World Markets Corp bought a new stake in shares of Protagonist Therapeutics during the 4th quarter worth $336,000. Vestcor Inc purchased a new position in Protagonist Therapeutics in the third quarter worth $334,000. Tower Research Capital LLC TRC grew its position in Protagonist Therapeutics by 2,211.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,339 shares of the company’s stock worth $295,000 after acquiring an additional 5,108 shares in the last quarter. Finally, Vise Technologies Inc. bought a new position in Protagonist Therapeutics in the fourth quarter valued at $262,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group boosted their target price on shares of Protagonist Therapeutics from $65.00 to $95.00 and gave the company a “neutral” rating in a report on Tuesday, March 3rd. Jefferies Financial Group raised their price target on Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. HC Wainwright lifted their price target on Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research report on Friday, January 30th. TD Cowen boosted their price objective on Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, Citizens Jmp increased their price objective on Protagonist Therapeutics from $102.00 to $112.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $101.08.

Read Our Latest Report on PTGX

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.

See Also